VTGN logo

VTGN
VistaGen Therapeutics Inc

18,035
Mkt Cap
$124.87M
Volume
458,061.00
52W High
$4.52
52W Low
$1.90
PE Ratio
-2.57
VTGN Fundamentals
Price
$3.90
Prev Close
$4.07
Open
$4.11
50D MA
$3.57
Beta
1.45
Avg. Volume
534,958.48
EPS (Annual)
-$1.67
P/B
2.10
Rev/Employee
$8,526.32
Loading...
Loading...
News
all
press releases
Vistagen to Present at The Menopause Society 2025 Annual Meeting
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product...
Business Wire·11d ago
News Placeholder
More News
News Placeholder
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates
VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of 0.00% and -62.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Exact Sciences (EXAS) Surpasses Q2 Earnings and Revenue Estimates
Exact Sciences (EXAS) delivered earnings and revenue surprises of +1,200.00% and +4.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?
Inovio (INO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3mo ago
News Placeholder
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates
Zacks·6mo ago
News Placeholder
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates
Zacks·6mo ago
News Placeholder
Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates
Zacks·6mo ago
News Placeholder
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates
Zacks·6mo ago
News Placeholder
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates...
Business Wire·8mo ago
News Placeholder
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates...
Business Wire·9mo ago

Latest VTGN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.